Antimicrobial resistence of Shigella species isolated during 2004 and 2005 from selected sites in Zimbabwe.
OBJECTIVE
To determine the predominant serotype and antibiotic sensitivity pattern of Shigella isolates during 2004 and 2005 in Zimbabwe.


METHODS
Cross sectional study.


METHODS
National Microbiology Reference Laboratory (NMRL), Harare, Zimbabwe.


METHODS
259 clinical isolates of Shigella species isolated during 2004 and 2005 in Zimbabwe were studied. These samples had been referred to the NMRL for further testing.


METHODS
Serotype and antibiotic sensitivity pattern of Shigella species.


RESULTS
Of the 259 clinical isolates of Shigella tested the following species were serotyped; 141 (54.4%) were S. flexneri; 70 (27%) S. sonnei; 38 (14.7%) S. dysenteriae and 10 (3.9%) S. boydii. About 4% of all Shigella isolates tested showed full sensitivity to commonly used antibiotics, 20.8% were resistant to one antibiotic only while 75.3% were resistant to at least two antibiotics. The most common resistance among Shigella species was to cotrimoxazole (89%), tetracycline (73%), ampicillin (49%) and chloramphenicol (41%). High susceptibility among Shigella species was observed to nalidixic acid (86%), ciprofloxacin (99%) and ceftazidine (99%).


CONCLUSIONS
There was a low drug resistance of Shigella species to nalidixic acid, a drug of choice in Zimbabwe, except among Shigella dysenteriae type 1 strains. Continuous monitoring of the susceptibility patterns of Shigella species is important in order to detect the emergence of drug resistance and to update guidelines for antibiotic treatment in shigellosis.
Ndlovu
N
N
National Microbiology Reference Laboratory, Southerton, Harare, Zimbabwe.
Tarupiwa
A
A
Mudzori
J T
JT
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D012703:Serotyping; D012760:Shigella / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D015030:Zimbabwe
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents